Altimmune, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Altimmune announced initiation of the global PERFORMA Phase 3 trial in MASH (metabolic dysfunction-associated steatohepatitis) with 52-week data expected in 2029, positive topline results from the RECLAIM Phase 2 trial in alcohol use disorder showing statistically significant reduction in heavy drinking days, and completion of patient enrollment in the RESTORE Phase 2 trial in alcohol-associated liver disease. The company holds $519 million in cash, cash equivalents, and investments as of June 30, 2026, bolstered by a $225 million gross proceeds public offering completed in April 2026. Q2 2026 net loss was $22.8 million (vs. $22.1 million in Q2 2025); R&D expenses were $18.7 million.
Why this rating
Phase 3 initiation in lead indication (MASH) and positive Phase 2 data in secondary indications are pivotal inflection points for clinical-stage company. $519M cash runway is substantial relative to ~$327M market cap, enabling multi-year trials. However, PERFORMA readout is 3+ years away, and success not guaranteed.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.